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Abstract
Cardiac troponins are released into the bloodstream as a result of myocardial injury and their 
detection in the blood is in routine clinical use for the diagnosis of myocardial infarction. A range of
other cardiac and non-cardiac conditions may also cause a rise in troponin. A number of recent 
studies have found that high-sensitivity troponin is significantly associated with future coronary 
events in people without prior cardiovascular disease. Some studies have investigated its 
incremental benefit in risk prediction models, but have been too small to show a statistically 
significant improvement in the C statistic. Nevertheless, troponin measurements should be 
considered as a cardiovascular risk marker among healthy people as well as a diagnostic marker for 
myocardial infarction.
Cardiac troponins are proteins found in cardiac muscle cells, which can be released into the 
bloodstream as a result of myocardial injury. Their detection in the blood been used for over 15 
years to aid the diagnosis of myocardial infarction. Troponin forms part of the troponin-
tropomyosin complex that regulates cardiac muscle contraction, and consists of three subunits: 
troponin T which binds to tropomyosin, troponin C which binds calcium ions, and troponin I which 
is the inhibitory subunit. When the complex is activated by calcium ions, the tropomysin strands 
move to reveal myosin binding sites on the actin filaments, initiating muscle contraction.[1] 
Assays for troponins I and T are in routine clinical use for measuring their concentration in the 
blood. Detection of a rise (and fall) in troponin is a key component of the current universal 
definition of myocardial infarction, and troponins are used clinically to differentiate acute coronary 
syndromes into unstable angina (no troponin release) and myocardial infarction (cardiac muscle 
damage due to ischaemia).[2] However, a range of other cardiac conditions (such as 
cardiomyopathies, arrhythmias and heart failure) and non-cardiac conditions (such as hypoxia, 
sepsis, pulmonary embolism, renal failure, stroke and strenuous exercise) may also cause a rise in 
troponin.[2] This means that troponin results always have to be interpreted in the context of the 
patient’s history and other investigation results.
Healthy people have a very low concentration of troponin in the blood, and early (standard 
sensitivity) troponin assays were not precise enough to quantify this, but could allow a crude 
differentiation into 'detectable' versus 'non-detectable' troponin. Daniels et al. studied 5592 people 
without coronary disease in the Multi-Ethnic Study of Atherosclerosis, and found that male sex, 
diabetes, renal impairment, and higher NT-proBNP were associated with detectable troponin T.[3] 
There was also an association with ethnicity: African Americans were more likely to have 
detectable troponin T, whereas Chinese Americans were less likely. Study participants were 
followed for median 10.2 years and accrued 370 cardiovascular events (myocardial infarction, 
cardiac arrest or stroke). Individuals with detectable troponin T had a fourfold increased risk of 
coronary heart disease (95% confidence interval (CI) 2.3, 6.8; p < 0.001) and a threefold increased 
risk of cardiovascular disease (95% CI 1.8, 4.8; p < 0.001) compared with individuals with 
undetectable troponin T.[3]
The study by Iribarren and colleagues [4] takes advantage of the quantification of low levels of 
troponin in healthy people that is possible using new high-sensitivity troponin assays. The study 
recruited 1135 people with no prior cardiovascular disease from the Kaiser Permanente health 
system in northern California, and followed them up for median 11.3 years. Baseline high-
sensitivity troponin I in the top quartile (>5.5 ng/L in men, >4.2 ng/L in women) was associated 
with increased risk of coronary heart disease compared to the bottom quartile, even after adjustment
for age, sex, race, ethnicity, education level, diabetes, C-reactive protein, renal function (eGFR) and
the Framingham risk score (hazard ratio 2.47, 95% CI 1.55, 3.93).[4]
These findings are consistent with those from other studies. In the AGES-Reykjavik study of 
5764 older Icelandic individuals (age 66-98 years), incidence of all-cause mortality, cardiovascular 
disease or coronary heart disease was significantly associated with increasing concentrations of 
troponin I.[5] In the Caerphilly study, Patterson et al. compared the strength of association of 
cardiac troponin concentrations with cardiovascular and non-cardiovascular mortality. They 
followed up 1773 Welsh men (667 with prior cardiovascular disease) for mean 15.4 years and found
that higher troponin was significantly associated with cardiovascular death (subhazard ratio 1.71 per
tertile increase, 95% CI 1.46, 1.99) but not non-cardiovascular death (subhazard ratio 1.00, 95% CI 
0.89, 1.11; p for interaction < 0.001).[6]
It is biologically implausible that circulating troponins cause increased risk of coronary disease; 
instead they may reflect the severity of the underlying atherosclerosis or subclinical myocardial 
ischaemia, or may be proxies for conditions associated with increased cardiovascular risk such as 
renal impairment. However, the exact biological mechanism underlying these findings is not clearly
understood.
Iribarren et al. also sought to investigate the utility of high sensitivity troponin I measurements in
cardiovascular risk prediction. Their sample size with 164 coronary events was too small so show a 
statistically significant increment in the C statistic, but the category-based net reclassification index 
was 18% (95% CI 8%, 30%).[4] Similarly, Welsh et al. found a non-significant improvement in 
classification when troponin T measurements were included in QRISK2 or ASSIGN cardiovascular 
risk prediction models applied to the British Regional Heart Study (3538 men) and MIDSPAN 
Family Study (1907 men and women) [7]. Further studies with larger sample sizes would be 
required to fully evaluate high sensitivity troponin in cardiovascular risk prediction among healthy 
people before it could be recommended for clinical use.
Investigating the prognostic significance of troponins in the general population may also help to 
inform the diagnosis of myocardial infarction, which relies on the interpretation of ‘abnormal’ 
troponin results, defined as greater than the 99th percentile upper reference limit. The determination 
of such reference ranges can be strongly influenced by the composition of the reference population.
[8] Longitudinal cohort studies may enable normality to be defined as the group with good 
prognosis, rather than individuals considered 'normal' based on prior history and current clinical 
features. Interpretation of troponin results using age and sex-specific reference ranges may help to 
avoid under- or over-diagnosis of myocardial infarction.
In conclusion, blood concentrations of cardiac troponins convey prognostic information in 
people without cardiovascular disease as well as those with acute coronary syndromes. This may 
herald a paradigm shift, with future use of troponin measurements for the evaluation of stable 
patients in primary care, as well as patients with acute coronary syndrome. However, studies to date
have been too small to evaluate whether any improvement in decision making as a result of 
including troponin in cardiovascular risk models improves outcomes or is cost-effective. Larger 
population-based cohort studies, with comprehensive risk factor and biomarker measurement, 
would be required to fully assess the clinical utility of troponins in cardiovascular risk prediction.
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